The lym Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the lym Hub cannot guarantee the accuracy of translated content. The lym and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Lymphoma & CLL Hub is an independent medical education platform, sponsored by Beigene, Johnson & Johnson and Roche, and supported through educational grants from Bristol Myers Squibb, Incyte, Lilly, and Pfizer. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View lym content recommended for you
Brentuximab vedotin combination receives EC approval for the treatment of adult patients with untreated Stage III Hodgkin lymphoma
On October 18, 2023, it was announced that brentuximab vedotin, a CD30-directed antibody-drug conjugate, in combination with doxorubicin, vinblastine and dacarbazine (AVD) received approval from the European Commission (EC) for the treatment of adult patients with previously untreated CD30+ Stage III Hodgkin lymphoma. This follows the recent positive opinion from the Committee for Medicinal Products for Human Use (CHMP) on September 14, 2023.1
This approval is based on key findings from the randomized phase III ECHELON-1 trial (NCT01712490) comparing brentuximab vedotin plus AVD to doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD). In 1,334 adult patients with previously untreated State III or IV classical Hodkin lymphoma.1 The study met its primary endpoint of modified progression-free survival as well as the secondary endpoint of overall survival (OS), demonstrating a statistically significant improvement in OS for the brentuximab vedotin plus AVD group.1 Additionally, the safety profile remained consistent with previous studies.1
References
Please indicate your level of agreement with the following statements:
The content was clear and easy to understand
The content addressed the learning objectives
The content was relevant to my practice
I will change my clinical practice as a result of this content